Analyst Split Sends Natera Stock Suddenly Sliding

Natera ( (NTRA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.

Natera shares were under pressure despite a wave of bullish analyst commentary, as one firm’s decision to trim its price target tempered the otherwise upbeat tone. The mixed message, with most targets rising but one being cut, left investors questioning whether the growth story is fully priced in and sparked profit‑taking after a strong run.

Morgan Stanley boosted its price target to $355 and reaffirmed an Overweight rating, joining several peers who also raised their forecasts. The higher targets signal growing confidence in Natera’s revenue trajectory and long‑term expansion, even as the lone downward revision injects a note of caution.

Promotion

Explore why XOVR invested in Kalshi and how it identifies innovative private companies before they reach the public markets.

Over the longer haul, Natera’s move to generating cash from its operations gives the company more breathing room to fund new products and clinical trials without constantly tapping investors for fresh capital. That financial flexibility can support steady growth and help the business weather market swings.

At the same time, the company is still not consistently profitable, and its margins depend heavily on how insurers decide to reimburse its tests and on costly cancer‑detection research. If those reimbursement decisions disappoint or R&D takes longer than expected to pay off, future earnings and cash flow could fall short of today’s optimistic expectations.

This story was written using TipRanks's AI tools and reviewed by a TipRanks editor.